Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 12;23:21. doi: 10.1186/s13058-021-01398-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 3 — Triple ER, CDK4/6, and FGFR1 blockade reverts resistance in FGFR1-positive models. a Relative plating efficiency (left) and example of colony assays (right) of parental MCF7, T47-D, and FGFR1-amplified HCC1428 or their FGFR1-overexpressing or LTED-R variants in response to vehicle, palbociclib (MCF7 cell lines, 50 nM; T47-D and HCC1428 cell lines, 100 nM), fulvestrant (MCF7 cell lines, 0.5 nM; T47-D cell lines, 1.5 nM and HCC1428 cell lines, 5 nM), DCC, palbociclib plus fulvestrant, or palbociclib plus DCC. b In the same model as in a, the observed resistance against palbociclib + fulvestrant/DCC was reverted by adding the FGFR1 inhibitor rogaratinib (1 μM), as evidenced by the relative-plating efficiency data. Statistically significant difference between either vehicle and all combinations or double and triple combinations are shown. Error bars: standard error. ***P < 0.001; **P < 0.01; *P < 0.05